Press Releases

Hepatorenal Syndrome Treatment Market Research, Measurement Activities, Analysis, Scientific Developments & Revolution To 2022-2030

Exponential Growth in Therapeutics Boosts Growth of Hepatorenal Syndrome Treatment Market

Improvements in the therapeutics landscape of the hepatorenal syndrome treatment market are creating new avenues in incremental opportunities for healthcare companies. Although surgical treatments dominate the hepatorenal syndrome (HRS) treatment market, analysts at anticipate an exponential growth for therapeutics in terms of market value share. Therapeutics are projected to rise from a market value share of ~1% in 2018 to ~6% by the end of 2027, in the hepatorenal syndrome treatment market. Thus, lucrative opportunities in the therapeutics landscape are attracting the attention of healthcare companies.

Get the sample copy of report@ https://qyresearchmedical.com/sample/111766

Healthcare companies are developing improved formulations of therapeutic drugs that are safe and effective for HRS patients. For instance, in May 2019, Mallinckrodt – a global specialty pharmaceutical company, announced the launch of Terlipressin – an investigational agent for the treatment of type 1 hepatorenal syndrome.

Since there are no treatments approved in the U.S. and Canada for HRS-1, healthcare companies are increasing their research efforts to reach full potential in terms of the enrollment of participants. Thus, active enrollment of participants in clinical studies will help enhance the credibility of research outcomes in the hepatorenal syndrome treatment market.

Health Commissions Recommend Albumin as Cost-effective Treatment Option for Cirrhosis and HRS

Complications of cirrhosis lead to HRS and progressive kidney failure amongst patients with severe liver damage. Hence, healthcare providers prescribe albumin to cirrhotic patients with acute decompensation. Albumin is gaining increased popularity in the hepatorenal syndrome treatment market, since it serves as a cost-effective treatment option for HRS and cirrhosis. As such, there is growing demand for albumin in hospitals and ambulatory surgical centers across Germany, Italy, and Spain.

Get a glimpse of the in-depth analysis through our Report Brochure

Healthcare companies in the hepatorenal syndrome treatment market are increasing their production capabilities of albumin, since the protein serves as a low-cost and effective alternative to saline, gelatin, and no fluid treatment of large volume paracentesis (LVP). It is found that, the combination of albumin with antibiotics is clinically more effective than antibiotics alone in the hepatorenal syndrome treatment landscape. To reduce the severe complications of cirrhosis amongst HRS patients, healthcare companies in the hepatorenal syndrome treatment market are increasing awareness about the combination therapy of albumin with vasoconstrictors.

Albumin is being increasingly used in combination with other drugs such as terlipressin. This trend is gaining increased popularity due to its low medical complication costs. Due to reduced rates of renal impairment and reduced mortality rates, health commissions across various countries are recommending the prescription of albumin to treat serious conditions of HRS.

Economic Evaluation Helps Companies Analyze Cost Difference for HRS Treatment Options

HRS is characterized by renal failure in patients suffering from advanced chronic liver disease (CLD). This disease condition has led to increased hospitalizations in the U.S. As such, the U.S. currently accounts for the highest revenue amongst all regions in the hepatorenal syndrome treatment market, with a value recorded at ~US$ 5 billion in 2018. Therefore, companies in the hepatorenal syndrome treatment market are increasing their efforts to introduce advanced treatment options for HRS patients in the U.S. However, it is found that, there is a growing need for cost-efficient treatment alternatives for the diagnosis of HRS in the U.S. Costly HRS treatments have created the problem of economic burden amongst patients. This has adversely affected the credibility of outcomes, as patients lack access to cost-efficient and effective treatment options.

Hence, companies in the hepatorenal syndrome treatment market are carrying out extensive research to analyze the number of hospitals that offer treatments at a higher cost. This is particularly compared with hospitals in the developing countries of Asia Pacific. For instance, it has been found that, the cost of treatment for HRS is less expensive in India as compared to the economic evaluation of treatment offered in Brazil. Companies in the hepatorenal syndrome treatment market are increasing research & development to devise strategies that reduce the economic burden on patients, and are increasing the availability of effective treatment options at U.S. hospitals.

Analysts’ Viewpoint

In 2027, surgical treatments are projected to account for ~94% market share of the hepatorenal syndrome treatment market. Hence, healthcare companies should focus on the application of evidence-based algorithms, catering to surgical and pharmacological options for patients suffering from HRS.

View full report@ https://qyresearchmedical.com/report/hepatorenal-syndrome-treatment-market-type-type-1-hepatorenal-syndrome-type-2-hepatorenal-syndrome-treatment-therapeutics-surgical-treatment-end-user-hospitals-clinics-ambulatory-surgical-centers-academi-019-2030/111766

However, surgical repair of umbilical hernia in cirrhotic patients has increased risks of high postoperative morbidity and mortality. To overcome this hurdle, companies should aid healthcare providers to increase their efficacy in elective surgery with perioperative preparations to ensure effective and safe outcomes after a surgery. Since HRS treatment is less expensive in Asia Pacific, healthcare companies should capitalize on this opportunity, as the region is estimated for exponential market growth amongst all the other regions in the landscape.

Global Hepatorenal Syndrome Treatment Market: Overview

The global hepatorenal syndrome treatment market was valued at ~US$ 11 Bn in 2018 and is projected to reach a value of ~US$ 16.7 Bn by 2027, expanding at a CAGR of ~5% from 2019 to 2027.

North America, Europe, and Asia Pacific were the major regional hepatorenal syndrome treatment markets in 2018. The hepatorenal syndrome treatment markets in North America and Asia Pacific are likely to expand at CAGRs of 5.1% and 4.8%, respectively, during the forecast period.

The global hepatorenal syndrome treatment market is projected to witness high growth, owing to promising effective therapies in the pipeline for addressing gaps in the treatment of hepatorenal syndrome.

Increase in the prevalence and incidence of hepatorenal syndrome and development and launch of various pipeline drugs for the treatment of hepatorenal syndrome in the near future are expected to drive the global HRS treatment market during the forecast period.

Global Hepatorenal Syndrome Treatment Market: Significant Growth Prospects in Developing Countries

Developing economies in Asia Pacific, Latin America, and Eastern Europe hold great opportunities for the hepatorenal syndrome treatment market, owing to their increasing population, coupled with rise in health care-related customer expenditure brought about by the rise in their economies.

Continuous technological advancements in surgical procedures for liver and kidney diseases with respect to higher efficacy and targeted therapeutic role have widened the scope for players present in the hepatorenal syndrome treatment market.

New drugs with combined features of reduced side-effects and higher efficacy have a significant potential for growth in the hepatorenal syndrome treatment market. Thus, the introduction of new products can help new entrants establish their foothold in the hepatorenal syndrome treatment market.

Increase in Disease Awareness & Patient Support Programs to Boost Hepatorenal Syndrome Treatment Market

In order to reduce mortality and morbidity rates, governments in developed and developing countries are conducting awareness campaigns to encourage people to go for the early diagnosis of kidney and liver diseases. This, in turn, is expected to increase awareness regarding hepatorenal syndrome diagnosis and treatment, thereby boosting the growth of the global hepatorenal syndrome treatment market.

For instance, every 2nd Thursday of March is observed as World Kidney Day. It is a global awareness campaign to increase awareness about chronic kidney diseases and the introduction of healthy changes in life to reduce risk factors.

Moreover, in developing countries such as India, hospitals are raising awareness about these diseases. For instance, in February 2016, Noida-based Jaypee Hospital in India organized a kidney and liver disease awareness campaign.

Global Hepatorenal Syndrome Treatment Market: Fast Track and Orphan Drug Designations

In 1983, recognizing that adequate drugs for rare disorders had not been developed in the U.S., the Congress passed the Orphan Drug Act to provide incentives to induce companies to develop drugs for THE treatment of rare and neglected diseases. Orphan drug status is granted to drugs and biologics that are intended for the diagnosis, prevention, or treatment of rare diseases or disorders that affect fewer than 200,000 people in the U.S. Orphan drugs are given priority review, allowing them to be assessed within six months for approval.

Hepatorenal syndrome is a form of impaired kidney function that occurs in individuals with advanced chronic liver disease. AROUND 40% of people with ascites and cirrhosis develop hepatorenal syndrome.

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111766/2900

In case of hepatorenal syndrome treatment, several drugs have received orphan drug designation, thereby accelerating their approval process, and this can act as a factor pushing the growth of the hepatorenal syndrome treatment market.

For instance, in November 2004, ESP Pharma, Inc. announced that FDA had granted Orphan Drug Designation to Terlipressin for the treatment of hepatorenal syndrome Type 1, providing seven years marketing exclusivity upon the completion of clinical studies and FDA approval of the drug for this indication.

Additionally, in November 2018, BioVie Inc. announced that the FDA has granted Orphan Drug designation to its Terlipressin drug for the treatment of hepatorenal syndrome (HRS).

The designation for orphan drug allows manufacturers to qualify for various incentives, including tax credits for qualified clinical trials, along with seven years of market exclusivity upon regulatory approval. This is likely to drive the hepatorenal syndrome treatment market during the forecast period.

Global Hepatorenal Syndrome Treatment Market: Competition Landscape

Strategic collaborations among key manufacturers and companies having their products in clinical trials to expedite the process of research & development are likely to help thousands of patients suffering from hepatorenal syndrome. Rise in the trend of collaborations is projected to drive the hepatorenal syndrome treatment market by fueling novel product launches.

In 2010, Ikaria, Inc. entered into a strategic collaboration with Orphan Therapeutics to acquire the rights of Orphan Therapeutics’ drug ‘LUCASSIN’ in North America and Australia. Ikaria, Inc. holds all the necessary rights to manufacture, develop, and commercialize LUCASSIN in Mexico, the U.S., and Australia.

Additionally, in April 2017, Mallinckrodt plc acquired Ikaria, Inc. The deal was valued at US$ 2.3 Bn.

Such collaborations are likely to enhance the chances of the development of comprehensive treatment for hepatorenal syndrome, thereby improving the survival rate of patients, and eventually surging the growth of the hepatorenal syndrome treatment market.

Hepatorenal Syndrome Treatment Market – Key Questions That Have Been Answered

  • What are the key factors that are influencing the hepatorenal syndrome treatment market in each region?
  • What are the major developments that will take place in the hepatorenal syndrome treatment market during the forecasted period of 2019-2027?
  • What are the revenue figures of the global hepatorenal syndrome treatment market by type, treatment, end user, and region?
  • What are the prevalent trends and how do they affect the future scope of the hepatorenal syndrome treatment market?
  • How is the rising prevalence of hepatorenal syndrome going to influence the need for surgical and therapeutic treatment options in the hepatorenal syndrome treatment market landscape?

Hepatorenal Syndrome Treatment Market – Segmentation

In order to understand the granular and broader nuances of the market, the segmentation of the hepatorenal syndrome treatment market has been done on the basis of type, treatment, end user, and region. This is one way by which incremental opportunities can be assessed in the hepatorenal syndrome treatment market.

Type

  • Type 1
  • Hepatorenal
  • Syndrome
  • Type 2
  • Hepatorenal
  • Syndrome

Treatment

  • Therapeutics
  • Terlivaz
  • Glypressin
  • Lucassin
  • Hepatoren
  • Surgical Treatment
  • Liver Transplantation
  • Surgical Shunting
  • Renal Replacement Therapy
  • Others

End User

  • Hospitals &
  • Clinics
  • Ambulatory
  • Surgical
  • Centers
  • Academic &
  • Research
  • Institutes
  • Others

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

TABLE OF CONTENT

1. Preface

1.1. Report Scope and Market Segmentation

1.2. Research Highlights

2. Assumptions and Research Methodology

2.1. Assumptions and Acronyms Used

2.2. Research Methodology

3. Executive Summary

3.1. Global Hepatorenal Syndrome Treatment Market: Market Snapshot

4. Market Overview

4.1. Global Hepatorenal Syndrome Treatment Market: Type Overview

4.2. Global Hepatorenal Syndrome Treatment Market: Key Industry Developments

4.3. Market Dynamics

4.4. Drivers and Restraints Snapshot Analysis

4.5. Drivers

4.5.1. Fast track and orphan drug designations

4.5.2. Increase in strategic collaboration among key players

4.6. Restraints

4.6.1. Side-effects and risks related to drug usage

4.6.2. Stringent regulatory requirements

4.7. Opportunities

4.8. Global Hepatorenal Syndrome Treatment Market Revenue Projections (US$ Mn), 2017–2027

5. Key Insights

5.1. Pipeline Analysis

5.2. Regulatory Scenario by Region/Country

5.3. Key Industry Events (Mergers, Acquisitions, Collaborations, Launch & Approvals, etc)

5.4. Prevalence of Liver & Kidney Diseases by Region/Globally

6. Global Hepatorenal Syndrome Treatment Market Analysis, by Type

6.1. Introduction

6.2. Global Hepatorenal Syndrome Treatment Market Value and Forecast, by Type

6.2.1. Type 1 Hepatorenal Syndrome

6.2.2. Type 2 Hepatorenal Syndrome

6.3. Global Hepatorenal Syndrome Treatment Market Analysis, by Type

6.4. Global Hepatorenal Syndrome Treatment Market Attractiveness Analysis, by Type

7. Global Hepatorenal Syndrome Treatment Market Analysis, by Treatment

7.1. Introduction

7.2. Global Hepatorenal Syndrome Treatment Market Value and Forecast, by Treatment

7.2.1. Therapeutics

7.2.1.1. Terlivaz

7.2.1.2. Glypressin

7.2.1.3. Lucassin

7.2.1.4. Hepatoren

7.2.2. Surgical Treatment

7.2.2.1. Liver Transplantation

7.2.2.2. Surgical Shunting

7.2.2.2.1. Peritoneovenous Shunting

7.2.2.2.2. Transjugular Intrahepatic Portosystemic Shunt (TIPS)

7.2.2.2.3. Others

7.2.2.3. Renal Replacement Therapy

7.2.2.4. Others

7.3. Global Hepatorenal Syndrome Treatment Market Analysis, by Treatment

7.4. Global Hepatorenal Syndrome Treatment Market Attractiveness Analysis, by Treatment

8. Global Hepatorenal Syndrome Treatment Market Analysis, by End-user

8.1. Introduction

8.2. Global Hepatorenal Syndrome Treatment Market Value and Forecast, by End-user

8.2.1. Hospitals & Clinics

8.2.2. Ambulatory Surgical Centers

8.2.3. Academic & Research Institutes

8.2.4. Others

8.3. Global Hepatorenal Syndrome Treatment Market Analysis, by End-user

8.4. Global Hepatorenal Syndrome Treatment Market Attractiveness Analysis, by End-user

9. Global Hepatorenal Syndrome Treatment Market Analysis, by Region

9.1. Global Hepatorenal Syndrome Treatment Market Value and Forecast, by Region, 2017–2027

9.1.1. North America

9.1.2. Europe

9.1.3. Asia Pacific

9.1.4. Latin America

9.1.5. Middle East & Africa

9.2. Global Hepatorenal Syndrome Treatment Market Analysis, by Region

9.3. Global Hepatorenal Syndrome Treatment Market Attractiveness Analysis, by Region

10. North America Hepatorenal Syndrome Treatment Market Analysis

………

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111766/2900

You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333

About Us

QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.

For Latest Update Follow Us:

https://www.linkedin.com/company/qyresearch-medical/

https://www.facebook.com/QYResearch-Medical-108186514228917/

https://twitter.com/qyresearchmedi

Show More

Related Articles

Back to top button